Champions Oncology (NASDAQ:CSBR) last issued its earnings results on Thursday, September 14th. The biotechnology company reported ($0.06) EPS for the quarter. The firm had revenue of $5.03 million during the quarter. Champions Oncology had a negative net margin of 29.87% and a negative return on equity of 338.01%.
Shares of Champions Oncology (NASDAQ CSBR) opened at $3.76 on Tuesday. Champions Oncology has a twelve month low of $2.09 and a twelve month high of $4.79.
Champions Oncology Company Profile
Champions Oncology, Inc is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.
What are top analysts saying about Champions Oncology Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Champions Oncology Inc and related companies.